Content
All Posts > Content under Healthcare
Premarket Biotech Digest – AMGN Announces Positive Results, FOLD Completes Analysis Plan, JNJ Files Lawsuit
Article By:
KKD Healthcare Analytics
Read
Monday, May 22, 2017 9:41 AM EDT
Amgen Inc. announced that it has received positive results from a Phase 3 clinical trial. AstraZeneca announced selling the European rights to its aging beta-blocker heart drug Seloken to Italian company Recordati.
GlycoMimetics Surges 100% On Breakthrough Therapy Designation
Article By:
Terry Chrisomalis
Read
Sunday, May 21, 2017 11:52 PM EDT
On Thursday, GlycoMimetics surged as high 100% after the company announced that it had received FDA breakthrough therapy designation.
In this article: GLYC
Week In Review: Shanghai Pharma Considers $4 Billion Bid For Germany's Stada
Article By:
ChinaBio® Today
Read
Saturday, May 20, 2017 11:46 AM EDT
Shanghai Pharma may bid $4 billion to acquire Stada Arzneimittel, a German generic drugmaker. Stada has already accepted a similar offer from a consortium formed by two private equity firms -- Bain and Cinven.
Argenx Joins Nasdaq Parade Following G1 Therapeutics With Another IPO Success
Article By:
Lorimer Wilson
Read
Thursday, May 18, 2017 5:45 PM EDT
Today's IPO by Argenx SE has proven to be a success as it was up 35% at the close of the trading day.Yesterday's IPO by G1 Therapeutics was also a success closing the day up 10.67% above its initial price.
4 Large-Cap Drug Stocks To Buy Post Q1 Earnings
Article By:
Sweta Killa
Read
Thursday, May 18, 2017 3:20 PM EDT
The Medical sector is among the sectors that has consistently been recording earnings growth over the last few quarters. The sector, which had recorded earnings growth of 4.5% on revenue growth of 5.2% in Q4.
Repros Announces Pricing Of $3.0 Million Public Offering Of Common Stock And Warrants To Purchase Common Stock
Article By:
NASDAQ GlobeNewswire
Read
Thursday, May 18, 2017 3:12 PM EDT
Repros Therapeutics Inc., announced today that it has entered into an underwriting agreement to sell in a public offering 2,744,125 shares of the Company’s common stock.
In this article: RPRX
Shire Ltd.'s $6 Billion Bet On Drug For Hereditary Angioedema Pays Off With Stellar Phase III Data
Article By:
Lorimer Wilson
Read
Thursday, May 18, 2017 1:54 PM EDT
Shire Ltd. bought Dyax for $6 billion in 2015 for its new drug for hereditary angioedema. Shire CEO Flemming Ornskov says their multi-billion dollar bet paid off with stellar Phase III data for the drug, now called lanadelumab.
In this article: SHPG
Endologix, Inc. Shares Dip Down On Update On Nellix Timetable To Get To US Market
Article By:
TickerTV
Read
Thursday, May 18, 2017 11:35 AM EDT
ELGX opened trading yesterday at $6.69 which was down from the previous day’s trading close of $6.80. Shares closed trading yesterday at $6.73 and spiked down after the market closed to $5.50, equivalent to an 18% decrease from the closing price.
In this article: ELGX